Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Atlanta Braves Holdings reported third quarter 2026 financial results, with total revenue increasing 4% to $325 million driven by higher baseball event revenue and mixed-use development rental income. Operating income declined significantly to $9 million from $39 million in the prior year period, primarily due to increased player salaries. The company highlighted a 14% increase in average regular season home game attendance and the successful first season of its direct-to-consumer platform, BravesVision.
Siebert Financial Corp. appointed Richard S. Gebbia and David J. Gebbia as Co-Chief Executive Officers, effective November 4, 2026. They succeed John J. Gebbia, who will step down from the CEO role but remain as Chairman of the Board.
Neuronetics reported Q3 2026 total revenue of $42.0 million, a 12.5% increase year-over-year, driven primarily by 20.1% growth in its Greenbrook clinic segment. The company achieved a significant turnaround in profitability, reporting positive Adjusted EBITDA of $1.9 million and income from operations of $0.5 million compared to losses in the prior year period.
Term
Q3 2026
“This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation.”
Dan Reuvers, President and Chief Executive Officer of Neuronetics
Peabody Energy reported Q3 2026 financial results with a net loss of $32.8 million and Adjusted EBITDA of $97.5 million, showing improved momentum across its seaborne operations. The company also declared a quarterly dividend of $0.075 per share and completed the repurchase of $38.9 million of its 2028 convertible notes.
Term
Q3 2026
“The third quarter demonstrated improving momentum across the portfolio with all segments reporting positive Adjusted EBITDA while our seaborne operations benefited from higher pricing. During the quarter, we worked through higher-cost faulted conditions at Centurion, which slowed advance rates, although the mine still reached its third quarter sales targets.”
Eagle Nuclear Energy M&A Deal with Noble Plains Uranium Corp.
Eagle Nuclear Energy Corp. has signed a binding letter of intent to acquire 100% of Noble Plains Uranium Corp. in an all-stock transaction. The deal values Noble Plains at CAD $0.125 per share, a 92% premium, and will expand Eagle's domestic uranium portfolio into Wyoming's Powder River and Shirley basins.
XPEL, Inc. reported third quarter 2026 revenue of $137.8 million, a 9.9% increase year-over-year, driven by gross margin expansion to 44.6%. Net income grew 26.3% to $16.3 million, while the company highlighted ongoing progress with its manufacturing investments in San Antonio and China.
Term
Q3 2026
“We delivered a solid third quarter in a challenging environment, growing revenue nearly 10% and expanding gross margin for the third consecutive quarter. Our manufacturing investments in San Antonio and China remain on track, and we are confident they will drive meaningful margin expansion in the years ahead.”
NewAmsterdam Pharma reported a net loss of $130.0 million for the nine months ended September 30, 2026, compared to $128.9 million in the prior year period. Revenue increased significantly to $25.9 million, primarily driven by $19.2 million in the third quarter, while the company maintained a strong liquidity position with $423.1 million in cash and cash equivalents.
Spectrum Brands Holdings Signs $1.6B M&A Deal with Helen of Troy Limited
Spectrum Brands' joint venture, Empower Brands, has submitted a non-binding proposal to acquire all outstanding shares of Helen of Troy Limited for $37.00 per share in cash. The deal implies an enterprise value of approximately $1.6 billion and represents a 31% premium over the target's 30-day volume-weighted average share price. Empower Brands, which is jointly owned by Spectrum Brands and Oaktree Capital Management, already holds a 4.5% stake in Helen of Troy.
Madison Square Garden Entertainment Financial Results
Madison Square Garden Entertainment Corp. reported fiscal first quarter 2027 revenues of $217.1 million, a 37% year-over-year increase driven by a record number of concerts at The Garden. The company achieved operating income of $9.7 million, a significant improvement from a loss in the prior year, and repurchased $25 million of its Class A common stock during the quarter.
Term
Q1 2027
“Our business is off to a strong start in fiscal 2027. We expect our live entertainment offerings to continue benefiting from healthy demand and we remain well positioned to drive robust growth in both revenue and adjusted operating income this fiscal year.”
Royalty Pharma reported 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026, driven by strong performance from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.50 billion to $3.55 billion. Management highlighted $1.9 billion in announced transactions year-to-date, including new royalties on Zoryve and Mimrylo.
Term
Q3 2026
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra.”
Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board
NCR Atleos Corp reported its financial results for the period ending September 30, 2026, highlighting a pending merger transaction with The Brink’s Company. The filing details risks related to its separation from NCR Voyix and ongoing business transformation, while reporting 73,939,883 shares of common stock outstanding as of October 28, 2026.
Fidelity National Information Services Financial Results
Fidelity National Information Services (FIS) reported third quarter 2026 revenue of $3.5 billion, a 27% increase on a GAAP basis, driven by the acquisition of Total Issuing Solutions. The company updated its full-year 2026 outlook, projecting adjusted revenue growth of 28-29% and free cash flow between $2.15 billion and $2.25 billion.
“Client demand remains strong, and we are continuing to invest in what our clients care about most, security and innovation. These investments will build a more recurring, predictable revenue base for FIS. The long-term payoff is significantly deeper client relationships, a stronger competitive position, and a business built for durable growth.”
NewAmsterdam Pharma reported third quarter 2026 financial results and highlighted the European Commission's approval of Ubeslo and Evlarco for hypercholesterolaemia. The company ended the quarter with $643.1 million in cash and expects an interim analysis of its PREVAIL cardiovascular outcomes trial in Q4 2026.
“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027.”
Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma
Medline reported Q3 2026 net sales of $7.9 billion, a 10.4% increase year-over-year, driven by new customer signings and existing customer growth. The company raised its full-year organic sales guidance and announced a new $1 billion share repurchase program authorized by the Board of Directors.
Term
Q3 2026
“Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business. Our commercial execution remains strong, including continued progress toward our annual total new customer signings goal.”
L.B. Foster reported strong Q3 2026 results with sales increasing 21.5% to $168.0 million and net income growing 56.5% to $6.8 million. The company generated $23.6 million in operating cash flow, reducing total debt to $28.7 million, its lowest level in a decade.
Term
Q3 2026
“We started the second half of the year with strong momentum, delivering meaningful growth in sales, profitability, and cash generation during the third quarter. Sales increased 21.5% over the prior year quarter, reflecting strong growth across both segments, while Adjusted EBITDA increased 15.1%.”
John Kasel, President and Chief Executive Officer
“Our third quarter operating cash flow of $23.6 million enabled us to reduce total debt by $19.3 million during the quarter and by $30.0 million compared to the prior year quarter, to the lowest level in over a decade.”
Scotts Miracle-Gro reported fiscal 2026 full-year net sales of $3.29 billion, a 1% increase driven by branded product growth and e-commerce expansion. Non-GAAP adjusted EPS of $4.48 exceeded guidance, and the company strengthened its balance sheet by reducing its net leverage to 3.89x.
Term
FY2026
“I’m pleased with our performance and financial discipline in fiscal 2026, as we delivered on all our imperatives and significantly strengthened our balance sheet.”
Nate Baxter, president and CEO
“We met or exceeded our fiscal 2026 commitments for net sales, gross margin, EPS, free cash flow and leverage ratio.”
Mark Scheiwer, chief financial officer and chief accounting officer
NCR Atleos reported Q3 2026 revenue of $1.1 billion and net income of $97 million, representing a 273% year-over-year increase in net income. The company noted that its pending merger with The Brink’s Company is on track to close in early January 2027, with integration planning confirming the strategic rationale for the deal.
Term
Q3 2026
“Atleos delivered strong third quarter profit growth and a very good first nine months of 2026 despite revenue challenges from the war in the Middle East and some customers delaying buying decisions in anticipation of the combined companies new solutions.”
Tim Oliver, Atleos’ Chief Executive Officer
“As we close out the third quarter, our results continue to reflect disciplined execution against our internal plan. We have been able to deliver strong financial results with year-over-year Adjusted EBITDA and EPS growth of 10% and 24%, respectively.”
Vishay Intertechnology reported net revenues of $978.9 million for the fiscal quarter ended October 3, 2026, a significant increase from $790.6 million in the prior year. The company returned to profitability with net earnings of $59.0 million compared to a net loss of $7.9 million in the same period last year, supported by a follow-on public offering that raised $830.3 million.
Riot Platforms reported Q3 2026 financial results, highlighted by a massive 15-year, 910 MW powered land lease at its Corsicana campus with a leading Frontier AI Lab. The lease represents approximately $28 billion in total contract value and is expected to generate $1.8 billion in average annual net operating income.
“Today, we are excited to announce the largest lease in Riot’s history: a 15-year triple-net powered land lease with a leading Frontier AI Lab for the entirety of our Corsicana campus, representing 910 megawatts of critical IT capacity and approximately $28 billion of contracted revenue over the initial term.”
Jason Les, CEO of Riot
“The structure of this new lease matters as much as the scale. With total capital costs of approximately $6 million per IT megawatt, the Corsicana development will require about half the capital of a Tier 3 build while significantly limiting procurement, development, and ongoing operational risk to Riot.”
Latham Group, Inc. reported net sales of $182.2 million for the fiscal quarter ended September 26, 2026, an increase from $161.9 million in the prior year period. Net income for the quarter rose to $12.1 million compared to $8.1 million, despite a $5.0 million loss on the extinguishment and modification of debt.
Westlake Corporation reported third quarter 2026 net sales of $2.98 billion and net income of $6 million, or $0.05 per diluted share. Results were impacted by $58 million in identified items, primarily related to previously announced facility shutdowns in the Performance and Essential Materials (PEM) segment. Excluding these items, adjusted net income was $58 million, or $0.45 per share, with an EBITDA margin of 14%.
For the nine months ended September 27, 2026, Dine Brands Global reported total revenues of $715.0 million, an increase from $661.7 million in the prior year, primarily driven by a significant rise in company-owned restaurant revenues. However, net income decreased to $16.3 million from $29.3 million year-over-year, impacted by higher company-owned restaurant expenses and increased interest costs.
Westlake Chemical Partners LP reported Q3 2026 net income of $16.2 million, or $0.46 per unit, an increase from $14.7 million in the prior year period. The Partnership also declared its 49th consecutive quarterly distribution of $0.4714 per unit, supported by a trailing twelve-month coverage ratio of 1.09x. Results were driven by higher sales volumes and lower maintenance capital expenditures.
Term
Q3 2026
“We were pleased with the Partnership's performance in the third quarter of 2026, with net income, EBITDA and MLP distributable cash flow all increasing from the second quarter. Looking forward, we expect our earnings and cash flows to continue to benefit from the stability provided by our ethylene sales agreement with Westlake.”
Jean-Marc Gilson, President and Chief Executive Officer
Rapport Therapeutics is a clinical-stage biotechnology company that has incurred significant financial losses since inception and expects to continue doing so. As of November 2, 2026, the company had 59,279,630 shares of common stock outstanding and is focused on developing its lead product candidate, RAP-219, for neurological disorders.
Tronox Holdings plc announced that its Board of Directors has declared a quarterly cash dividend of $0.05 per share. The dividend is scheduled to be paid on January 15, 2027, to shareholders of record as of the close of business on November 16, 2026.
Polar Power announced it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement. Additionally, the company is launching Phase 2 of its restructuring program, targeting a total of $2 million in annualized cost savings following the $1.03 million already achieved in Phase 1.
Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.
Arrowhead Pharmaceuticals $400M Debt Financing with Sixth Street Lending Partners
Arrowhead Pharmaceuticals refinanced its existing senior secured term loans by entering into a new $400 million Amended and Restated Financing Agreement with Sixth Street. The new facility significantly lowers borrowing costs from a 15% fixed rate to SOFR plus 5.50%, extends the maturity to November 2031, and eliminates previous requirements to sweep commercial revenue or milestone payments for debt repayment.
Seaport Therapeutics Director Denice Torres Buys $99.3K of Stock
Denice Torres, Director, bought 5,000 shares of Seaport Therapeutics, Inc. at $19.86 a share, worth $99.3K in total on Nov 3, 2026. Shares held after the trade: 5,000.
For the nine months ended September 30, 2026, uniQure N.V. reported a net loss of $195.8 million, an increase from the $161.9 million loss in the prior year period. Total assets grew to $940.6 million, supported by a follow-on public offering and the exercise of pre-funded warrants which contributed to a significant increase in additional paid-in capital.